Celldex Therapeutics (NASDAQ: CLDX) reported that its Phase 2 study of barzolvolimab in prurigo nodularis (PN) did not meet its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE